Cellestia is giving hope to cancer patients who have no other treatment or therapy options by developing innovative targeted therapies. Our drug discovery platform is built on a unique mode of action of targeting protein-protein interactions (PPI) with small molecules. Together with companion diagnostics, Cellestia provides a first-in-class solution for NOTCH-driven cancers. Our clinical candidate drug CB-103 is targeting orphan cancers such as cancer of the salivary gland (adenoid cystic carcinoma) and a subtype of childhood leukaemia. At the same time, we are continuing to expand our portfolio through (i) targeting large cancer indications with CB-103, such as breast cancer, and (ii) developing novel PPI inhibitors for additionnal oncology indications. Cellestia is a privately-owned clinical-stage biopharma company (phase I) led by an experienced team of scientists, drug developers and business professionals.
Check out the corporate videos:
- Cellestia – A novel therapy for currently untreatable cancers
- Raj’s story (Cellestia’s Chief Scientific Officer)